相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs
Y. H. Lee et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2021)
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee et al.
CLINICAL DRUG INVESTIGATION (2020)
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
Y. H. Lee et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
Young Ho Lee et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2020)
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Janet Pope et al.
ADVANCES IN THERAPY (2020)
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials
Yoshiya Tanaka et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
Young Ho Lee et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis
Young Ho Lee et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: amatching-adjusted indirect comparison
B. Fautrel et al.
RMD OPEN (2020)
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
Tsutomu Takeuchi et al.
ARTHRITIS RESEARCH & THERAPY (2020)
The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?
Yoshiya Tanaka
RHEUMATOLOGY (2019)
2018 update of the APLAR recommendations for treatment of rheumatoid arthritis
Chak Sing Lau et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
S-C Bae et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2019)
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review
Jehanya Jegatheeswaran et al.
IMMUNOTHERAPY (2019)
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
Gwan Gyu Song et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2019)
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
Desiree van Der Heijde et al.
RMD OPEN (2019)
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
Sumit Kunwar et al.
CLINICAL RHEUMATOLOGY (2018)
Baricitinib: A Review in Rheumatoid Arthritis
Zaina T. Al-Salama et al.
DRUGS (2018)
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Stanley Cohen et al.
RHEUMATOLOGY AND THERAPY (2018)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pathogenetic insights from the treatment of rheumatoid arthritis
Iain B. McInnes et al.
LANCET (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
A. J. Kivitz et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Tofacitinib: A Review in Rheumatoid Arthritis
Sohita Dhillon
DRUGS (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
Roy M. Fleischmann et al.
RMD OPEN (2017)
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
Tatsuya Atsumi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka et al.
JOURNAL OF RHEUMATOLOGY (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2015)
A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis
Tsutomu Takeuchi et al.
Modern Rheumatology (2014)
Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial
Kazuhiko Yamamoto et al.
MODERN RHEUMATOLOGY (2014)
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Joel Kremer et al.
ANNALS OF INTERNAL MEDICINE (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Pawel Kawalec et al.
CLINICAL RHEUMATOLOGY (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
David C. Hoaglin et al.
VALUE IN HEALTH (2011)
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
Jeroen P. Jansen et al.
VALUE IN HEALTH (2011)
Phase II Study of Tofacitinib (CP-690,550) Combined With Methotrexate in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Yoshiya Tanaka et al.
ARTHRITIS CARE & RESEARCH (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
分享论文
